INCRUSE ELLIPTA Rx

Select the drug indication to add to your list

INCRUSE ELLIPTA

Asthma/COPD
Only 4 drugs may be compared at once

Generic Name and Formulations:

Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose.

Company:

GlaxoSmithKline

Select therapeutic use:

Indications for INCRUSE ELLIPTA:

Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema. 

Adult:

Take at same time every day. 1 inhalation every 24hrs.

Children:

Not established.

Contraindications:

Severe hypersensitivity to milk proteins.

Warnings/Precautions:

Not indicated for relief of acute bronchospasm. Do not initiate in rapidly or acutely deteriorating COPD. Do not exceed recommended dose. Reevaluate periodically. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Discontinue if paradoxical bronchospasm (use alternatives) or hypersensitivity reactions occur. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Severe hepatic impairment. Labor and delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Additive effects with concomitant other anticholinergic-containing drugs; avoid.

Pharmacological Class:

Anticholinergic.

Adverse Reactions:

Nasopharyngitis, URTI, cough, arthralgia; visual disturbances, paradoxical bronchospasm.

How Supplied:

Dry pwd inhaler—30 doses

INCRUSE ELLIPTA 30 blisters of 62.5mcg inhalers (Qty:1)

appx. price $330.00